Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugemalimab in Resectable Stage II-IIIA NSCLC
NCT06987734Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of sugemalimab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Started Jun 2025; status: recruiting.
02
Drugs
sugemalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06987734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06987734.